RecruitingPsoriasis
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Sponsor: Bristol-Myers Squibb
You may qualify if…
- ✓ Have been diagnosed with plaque psoriasis by a dermatologist
- ✓ Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
- ✓ Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes
You may not qualify if…
- ✕ Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
- ✕ Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history
Where it's recruiting
Massachusetts
Waltham
Source: ClinicalTrials.gov · NCT05744466 · last updated 2024-07-23